Adenovirus-mediated cancer gene therapy and virotherapy

Takuya Fukazawa, Junji Matsuoka, Tomoki Yamatsuji, Yutaka Maeda, Mary L. Durbin, Yoshio Naomoto

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalInternational Journal of Molecular Medicine
Volume25
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Neoplasm Genes
Adenoviridae
Genetic Therapy
Neoplasms
Oncolytic Virotherapy
Genes
Cause of Death
Stem Cells
Therapeutics

Keywords

  • Adenovirus
  • Gene therapy
  • Specific promoter
  • Virotherapy

ASJC Scopus subject areas

  • Genetics

Cite this

Adenovirus-mediated cancer gene therapy and virotherapy. / Fukazawa, Takuya; Matsuoka, Junji; Yamatsuji, Tomoki; Maeda, Yutaka; Durbin, Mary L.; Naomoto, Yoshio.

In: International Journal of Molecular Medicine, Vol. 25, No. 1, 2010, p. 3-10.

Research output: Contribution to journalArticle

Fukazawa, T, Matsuoka, J, Yamatsuji, T, Maeda, Y, Durbin, ML & Naomoto, Y 2010, 'Adenovirus-mediated cancer gene therapy and virotherapy', International Journal of Molecular Medicine, vol. 25, no. 1, pp. 3-10. https://doi.org/10.3892/ijmm_00000306
Fukazawa, Takuya ; Matsuoka, Junji ; Yamatsuji, Tomoki ; Maeda, Yutaka ; Durbin, Mary L. ; Naomoto, Yoshio. / Adenovirus-mediated cancer gene therapy and virotherapy. In: International Journal of Molecular Medicine. 2010 ; Vol. 25, No. 1. pp. 3-10.
@article{35f5dc7ff2ba4d89b2064f64c72e6855,
title = "Adenovirus-mediated cancer gene therapy and virotherapy",
abstract = "Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.",
keywords = "Adenovirus, Gene therapy, Specific promoter, Virotherapy",
author = "Takuya Fukazawa and Junji Matsuoka and Tomoki Yamatsuji and Yutaka Maeda and Durbin, {Mary L.} and Yoshio Naomoto",
year = "2010",
doi = "10.3892/ijmm_00000306",
language = "English",
volume = "25",
pages = "3--10",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Adenovirus-mediated cancer gene therapy and virotherapy

AU - Fukazawa, Takuya

AU - Matsuoka, Junji

AU - Yamatsuji, Tomoki

AU - Maeda, Yutaka

AU - Durbin, Mary L.

AU - Naomoto, Yoshio

PY - 2010

Y1 - 2010

N2 - Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.

AB - Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.

KW - Adenovirus

KW - Gene therapy

KW - Specific promoter

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=70549110920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70549110920&partnerID=8YFLogxK

U2 - 10.3892/ijmm_00000306

DO - 10.3892/ijmm_00000306

M3 - Article

C2 - 19956895

AN - SCOPUS:70549110920

VL - 25

SP - 3

EP - 10

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 1

ER -